Marielle Appenzeller

Ms. Marielle Appenzeller


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 August 2025 in Veterinary Sciences
Verified
Journal Article
Open access
PDF file
MAMarielle Appenzeller
Marielle Appenzeller
AKAlexandra Kehl
Alexandra Kehl
KTKatrin Törner
Katrin Törner
KJKatharina Charlotte Jensen
Katharina Charlotte Jensen
RKRobert Klopfleisch
Robert Klopfleisch
Heike Aupperle-LellbachHeike Aupperle-Lellbach
Heike Aupperle-Lellbach
The BRAF V595E mutation analysis in canine urothelial carcinomas (UCs) has found its way into routine diagnostics, but no data analysis has been published until now. The present study aimed to estimate the distribution of age, sex, and breed in 8365 canine diagnostic samples submitted for BRAF mutation analysis during 2018–2024. The specimens included 8215 urine samples, 17 cytological, and 133 histopathological specimens, and were submitted in cases of suspected UC, to rule out UC, or for screening purposes. All samples were tested for the BRAF V595E mutation using droplet digital PCR (ddPCR). The data were statistically analysed and logistic regression models (Odds Ratio (OR)) were calculated. Compared to samples from mixed-breed dogs, the specimens from Scottish Terriers (OR: 4.21), Shetland Sheepdogs (OR: 2.65), Beagles (OR: 2.33), Fox Terriers (OR: 1.92), Staffordshire Bull Terriers (OR: 1.86), Magyar Vizslas (OR: 1.77), Chihuahuas (OR: 1.70), and West Highland White Terriers (OR: 1.43) had a significantly increased probability of the presence of BRAF mutation indicating UC. The youngest BRAF-positive dogs of these predisposed breeds (n = 4) were 5 years old. In conclusion, screening tests in predisposed breeds may be recommended from the age of 5 years.

27 June 2025 in Veterinary Sciences
Verified
Journal Article
Open access
PDF file
AKAlexandra Kehl
Alexandra Kehl
Heike Aupperle-LellbachHeike Aupperle-Lellbach
Heike Aupperle-Lellbach
MBMaria Brockmann
Maria Brockmann
AWAnna-Lena van de Weyer
Anna-Lena van de Weyer
MAMarielle Appenzeller
Marielle Appenzeller
Katja SteigerKatja Steiger
Katja Steiger
Urothelial carcinoma (UC) is one of the most frequent tumors in dogs. Besides cytology, histology, and testing for a BRAF mutation, non-invasive biomarkers would benefit the early detection and therapy of UC. This study aimed to compare the detectability of miRNAs in urine sediment and supernatant and to assess their potential as biomarkers for UC. The study involved two phases with 47 canine samples in total; in a pilot trial, ten different miRNAs (miR-16, 21, 103b, 106b, 146, 155, 182, 221, 222, and 375) were isolated from the urine sediments and supernatants from seven healthy control dogs and seven dogs with UC. In a further step, eight miRNAs were isolated from urine sediments from 18 healthy dogs, 11 dogs with purulent cystitis, and 18 dogs with UC. The detectability of miRNAs was improved when isolated from the urine sediment compared with the supernatant. MiR-16 was not deregulated, and miR-106b showed significantly lower expression in cystitis compared with the control. Lower copy numbers were seen for miR-21, 182, 221, and 222 in cystitis cases compared with the controls and UC, respectively. Deregulation was observed for miR-155 and miR-375 between all three groups. A panel including miR-182, 221, 222, 155, and 375 has the potential to discriminate among all three groups in a two-step approach.

8 May 2026 in Veterinary Sciences
Verified
Journal Article
Open access
PDF file
MAMarielle Appenzeller
Marielle Appenzeller
Heike Aupperle-LellbachHeike Aupperle-Lellbach
Heike Aupperle-Lellbach
AKAlexandra Kehl
Alexandra Kehl
RKRobert Klopfleisch
Robert Klopfleisch
SBSimone de Brot
Simone de Brot
Molecular genetic approaches have become indispensable in veterinary medicine for early tumour detection, confirming histomorphological diagnoses, and non-invasive diagnosis using urine samples. In canine urothelial carcinoma (UC), molecular testing includes BRAFV595E mutation analysis and the identification of specific copy number alterations (CNAs). CNAs affect multiple genes simultaneously, leading to their overexpression or underexpression. Recurrent gene gains on canine chromosomes (CFA)13 and CFA36 and losses on CFA19 are highly prevalent in canine UCs. This study evaluates CNA test performance and the influence of tumour purity on CNA test results using 76 histologically confirmed UC tissue samples. The tumour region of each histopathological section was measured, and its proportion relative to the total tissue area was calculated. In total, 58/76 cases (76.3%) were CNA-positive, defined by a ratio greater than 1.23 for both CFA13/19 and CFA36/19. A total of 14/18 negative cases had a ratio > 1.23 for CFA13/19 or CFA36/19. The sensitivity of this CNA assay depends on the applied thresholds, with a tumour-to-total tissue ratio of ≥20% yielding positive CNA results in 84% of cases, rising to 89% at ≥40%. These findings indicate that <20% tumour content and a moderate to high proportion of copy number-neutral cells may be associated with reduced CNA detectability.